2019
DOI: 10.1002/gcc.22695
|View full text |Cite
|
Sign up to set email alerts
|

Liquid biopsies

Abstract: Liquid biopsy is based on minimally invasive blood tests and has a high potential to significantly change the therapeutic strategy in cancer patients, providing an extremely powerful and reliable noninvasive clinical tool for the individual molecular profiling of patients in real time. Liquid biopsy approaches include the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating miRNAs, and tumor‐derived extracellular vesicles (EVs) that are shed from primary tumors and their metas… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
82
0
2

Year Published

2019
2019
2023
2023

Publication Types

Select...
9
1

Relationship

2
8

Authors

Journals

citations
Cited by 127 publications
(90 citation statements)
references
References 114 publications
0
82
0
2
Order By: Relevance
“…In parallel, the oncologic management of advanced disease has been revolutionized by the advent of liquid biopsy, i.e., the analysis of tumoral material shed from primary tumors and their metastatic sites into peripheral blood, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). Major advantages of liquid biopsy analysis include its minimal invasiveness and ability to provide real-time information about the disease [5]. To date, the utility of liquid biopsy in EC has been scarcely explored [6].…”
Section: Introductionmentioning
confidence: 99%
“…In parallel, the oncologic management of advanced disease has been revolutionized by the advent of liquid biopsy, i.e., the analysis of tumoral material shed from primary tumors and their metastatic sites into peripheral blood, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). Major advantages of liquid biopsy analysis include its minimal invasiveness and ability to provide real-time information about the disease [5]. To date, the utility of liquid biopsy in EC has been scarcely explored [6].…”
Section: Introductionmentioning
confidence: 99%
“…Thus far, there are limitations on the biomarkers being used to predict treatment response. PDL-1 expression, DNA mismatch repair instability and increased tumor mutational burden (TMB) are the biomarkers currently used to indicate patient that might benefit from immunotherapy [126][127][128]. However, not all patients who test positive for these biomarkers will respond to treatment and patient with low PD-L1 expression have shown clinical benefit [129].…”
Section: Translation Of Predictive Biomarkersmentioning
confidence: 99%
“…The detection of cancer genomic markers in the circulatory system gives great potential for the use of 'liquid biopsy' in the early detection of disease, with tumors shedding fragmented DNA (circulating tumor DNA; ctDNA), extracellular vesicles, and cells (circulating tumor cells) into the bloodstream [36]. Detection of such markers allows for an early and ongoing, non-invasive, cost-effective approach toward more routine screening for cancer and monitoring of disease recurrence especially in difficult to access tumor sites.…”
Section: Human Genomicsmentioning
confidence: 99%